Medication info

CAPD 3 Balance Peritoneal Dialysis Solution

Prescription medicationSolutionInjection
Ingredient · strength
Sodium Chloride›11.279gCalcium Chloride Hydrate›0.5145gMagnesium Chloride Hexahydrate›0.2033gGlucose Hydrate›93.5gSodium Lactate 50%›15.69g
Manufacturer / importer
Fresenius Medical Care Korea Ltd.
Appearance
Colorless and transparent solution divided into A solution (left) and B solution (right) in the shape of A.
Packaging
Box of 100 [1 x 1500mL, 1 x 2000mL, 1 x 2500mL, 1 x 3000mL], Box of 400 [4 x 2000mL, 4 x 2500mL, 4 x 3000mL], Box of 600 [6 x 1500mL]
Approval status
Active

MFDS item code 200009105 · Notified 2000.07.21 · Insurance code 664300270,664300280,664300290,664300300

Summary

Main use
Peritoneal dialysis treatment in patients with acute or chronic renal failure
Who receives it
Adults
Adult administration
1. The attending physician should adjust the treatment method, number of procedures, exchange volume, dialysis time, and duration according to the patient’s condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid volume control. In adults, the usual procedure is to instill 1.5~2.5L into the peritoneal cavity per exchange, allow it to dwell for 4~8 hours, and then drain it; this process is performed 3~5 times daily. 4. If a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine’s exchange volume. 5. The glucose concentration should be selected according to the patient’s ultrafiltration needs and kept as low as possible

Ingredients

Importer
Fresenius Medical Care Korea Ltd.

Efficacy & effects

Peritoneal dialysis treatment in patients with acute or chronic renal failure

View approved original text

This medication is used for peritoneal dialysis in patients with acute and chronic renal failure. It is utilized to effectively excrete waste when kidney function is significantly impaired, making it difficult to eliminate body waste and excess fluid. This helps alleviate symptoms caused by renal failure and maintain the patient's health.

How it is given

Adult administration

1. The attending physician should adjust the treatment method, number of procedures, exchange volume, dialysis time, and duration according to the patient’s condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid volume control. In adults, the usual procedure is to instill 1.5~2.5L into the peritoneal cavity per exchange, allow it to dwell for 4~8 hours, and then drain it; this process is performed 3~5 times daily. 4. If a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine’s exchange volume. 5. The glucose concentration should be selected according to the patient’s ultrafiltration needs and kept as low as possible

Precautions

This medication is a dialysis solution for peritoneal dialysis, used to remove body waste and excess fluid through the patient's peritoneum. Patients should be cautious, as prematurely discontinuing treatment without receiving alternative renal therapies may pose a threat to life. Patients with a perforation of the diaphragm, severe abdominal burns, severe peritoneal adhesions, bleeding disorders, lactate metabolism disorders, severe electrolyte imbalance, recent abdominal surgery or inflammation should not use this medication. Additionally, patients who are mentally or physically unable to perform peritoneal dialysis should avoid administration. Patients taking digitalis preparations or suspected to have glucose metabolism disorders should regularly monitor serum potassium and blood glucose levels when using this medication. Extra caution is needed for patients who had abdominal surgery, have severe respiratory disorders, are immunocompromised, or are pregnant. Pain, bleeding, or inflammation may occur at the injection site, and symptoms like peritonitis or abdominal pain, gastrointestinal symptoms, electrolyte imbalance, and metabolic disorders may arise. Any abnormal symptoms should be reported to medical personnel immediately. During peritoneal dialysis, body weight, nutritional status, and serum electrolytes/metabolic conditions should be regularly monitored for appropriate management. This solution must be used under sterile conditions, and if the container is damaged or if the solution is cloudy or contains foreign substances, it should not be used. For children, the dosage should be adjusted, and elderly patients have a higher risk of hernia; thus, careful evaluation before dialysis is essential. In cases of overdose, side effects like dehydration, electrolyte imbalances, and hyperglycemia may occur, necessitating proper usage and management. The safety of this medication has not been established in pregnant or lactating women, so it should only be used when the benefits outweigh the risks. This medication is intended for peritoneal dialysis use only and should not be used as an injection. To prevent infections during peritoneal dialysis, manipulations should be conducted in a sterile environment, and the condition of the container must always be checked before use.

Side effects

Abdominal pain, bleeding, peritonitis, abdominal pain, cloudy discharge, fever, inflammation around the abdominal catheter, flushing, secretion, catheter rupture, subcutaneous inflammation in case of drainage difficulties, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal distension, intestinal obstruction, hypokalemia, hyponatremia, hypercalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoproteinemia, hyperglycemia, dyspnea due to diaphragm elevation, respiratory symptoms related to electrolyte disturbances, pulmonary edema, pleural effusion, edema, loss of amino acids or water-soluble vitamins, shoulder pain, fever, muscle cramps, hernia, hydrocele, obesity, weakness, syncope, fatigue, headache, dizziness, tachycardia, hypertension, hypotension, sclerosing encapsulating peritonitis, sepsis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air from entering and kept in a cool place below 25 degrees Celsius. It should also be kept away from freezing.

Appearance and packaging

Appearance

Colorless and transparent solution divided into A solution (left) and B solution (right) in the shape of A.

Package unit

Box of 100 [1 x 1500mL, 1 x 2000mL, 1 x 2500mL, 1 x 3000mL], Box of 400 [4 x 2000mL, 4 x 2500mL, 4 x 3000mL], Box of 600 [6 x 1500mL]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.